Nov 4, 4:03 PM ET
STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, down 12% from $94.7 million a year earlier, and net income of $5.6 million, or $0.11 per diluted share, versus $8.9 million, or $0.18, in the prior-year quarter. The prior-year quarter included $25.9 million of deferred China sales; excluding that, third-quarter net sales rose 21%, and the company said it expects gross margin to improve in the fourth quarter. The Board also authorized a share repurchase of up to $50 million, and the company reported no outstanding debt.
- Net sales were $83.4 million, down 12% from $94.7 million; up 21% excluding $25.9 million of deferred China sales recognized in the third quarter of 2025.
- Gross profit margin was 70.9%, compared with 82.2% in the prior-year quarter, which included deferred China revenue with no cost of sales.
- Net income was $5.6 million, or $0.11 per diluted share, versus $8.9 million, or $0.18, a year earlier.
- In September 2026 the Board authorized repurchases of up to $50 million of common stock; cash and investments were $206.4 million as of October 2, 2026, with no outstanding debt.
Read the filing on SEC.gov ↗
Sep 9, 5:37 PM ET
STAAR Surgical appointed David Bailey, its former President and Chief Executive Officer, as Chief Commercial Officer effective September 8, 2026. He reports to CEO Warren Foust, and the filing sets out his base salary, bonus target and equity awards, which shareholders can review in the offer letter filed as Exhibit 10.1.
- Appointed Chief Commercial Officer effective September 8, 2026; reports to Warren Foust, President and CEO
- Base salary at an annual rate of CHF 462,825 (approximately $575,000), with a 2026 target bonus of 60% of base salary, prorated
- Initial RSU grant valued at $850,000 vesting over three years, plus a 2026 long-term incentive award valued at $1,400,000, prorated
- Mr. Bailey previously served as STAAR's President and CEO from 2001 to 2008 and as President, International Operations, from 2008 to 2011
Read the filing on SEC.gov ↗
Aug 12, 4:04 PM ET
STAAR Surgical reported second-quarter 2026 results for the quarter ended July 3, 2026, with net sales of $93.5 million, up from $44.3 million a year earlier, and net income of $8.1 million, or $0.16 per diluted share, compared with a net loss of $16.8 million a year earlier. The filing furnishes the earnings release as Exhibit 99.1 and announces a conference call at 5:30 p.m. Eastern on August 12, 2026, where management will discuss the results. The company reported cash and investments of $181.5 million and no outstanding debt.
- Net sales of $93.5 million, up 111% year over year; sales excluding China were $41.2 million, up 6.0%
- China sales of $52.3 million; EMEA sales declined by a low single-digit percentage, with growth excluding the Middle East
- Net income of $8.1 million, or $0.16 per diluted share, versus a net loss of $16.8 million, or $0.34 per diluted share, a year ago
- Adjusted EBITDA of $20.0 million, or $0.39 per diluted share; cash and investments of $181.5 million at July 3, 2026
Read the filing on SEC.gov ↗
Aug 6, 11:04 AM ET
STAAR Surgical's board appointed Warren Foust, previously its President and COO, as President, CEO and a board member, effective August 4, 2026. Deborah Andrews, who had been Interim Co-CEO since February 2026, stays as Chief Financial Officer and was named Executive Vice President. The filing also details large equity grants to both executives, which will dilute shareholders as they vest.
- Warren Foust has been President and COO since March 2025 and joined STAAR in April 2023; his base salary is $730,000 annually.
- Foust's CEO grant includes 22,493 time-vesting RSUs, 40,471 time-vesting options and 131,830 performance-vesting options tied to $50, $75 and $100 share price hurdles.
- Deborah Andrews will cease as Interim Co-CEO, remain CFO and receive an option grant of 8,952 shares, 29,159 performance options and 4,975 RSUs.
- The filing furnishes a press release dated August 4, 2026 as Exhibit 99.1.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.